Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Quantum Biopharma Ltd. - Class B Subordinate Voting Shares
(NQ:
QNTM
)
13.46
+0.88 (+7.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Quantum Biopharma Ltd. - Class B Subordinate Voting Shares
< Previous
1
2
3
Next >
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Finalizes $2.35 Million Settlement with Former CEO Raza Bokhari
May 30, 2025
Via
Investor Brand Network
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
May 30, 2025
Dr. Raza Bokhari, Company’s Former CEO, Paid $2.35 Million USD in Non-Dilutive Cash to Cover Legal and Other Costs Determined in the Arbitral Award Over the Past 4 Years
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Announces Auditor Appointment and Name Change for Unbuzzd Wellness
May 29, 2025
Via
Investor Brand Network
Topics
Initial Public Offering
Exposures
Securities Market
Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.
May 29, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Receives Australian Ethics Approval for Phase 2 Trial of FSD202 in MCAS Patients
May 28, 2025
Via
Investor Brand Network
Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome
May 28, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Taps BitGo to Safeguard Crypto Assets
May 21, 2025
Via
Investor Brand Network
Quantum BioPharma Partners with BitGo to Securely Store its Crypto Currency Assets
May 21, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Signs Agreement to Advance MS Drug Toward Phase 2 Trial
May 20, 2025
Via
Investor Brand Network
Exposures
Product Safety
Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis
May 20, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000
May 19, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference
May 16, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Completes Dosing in Key Toxicity Studies for MS Drug Candidate
May 12, 2025
Via
Investor Brand Network
Exposures
Product Safety
Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis
May 12, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Files Amended $700M Market Manipulation Complaint in Federal Court
May 05, 2025
Via
Investor Brand Network
Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
May 05, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Appoints Anti-Corruption Advocate Kevin Malone as Board Advisor
April 24, 2025
Via
Investor Brand Network
Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time
April 24, 2025
From
Quantum BioPharma
Via
GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Appoints Anti-Corruption Advocate Kevin Malone as Board Advisor
April 22, 2025
Via
Investor Brand Network
Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor
April 22, 2025
From
Quantum BioPharma
Via
GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Issues Corporate Update
April 21, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Prevails in Legal Dispute With Former CEO
April 14, 2025
Via
Investor Brand Network
Topics
Bonds
Exposures
Debt Markets
Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario
April 14, 2025
Awards in favour of Quantum BioPharma Totalling $180,000 upheld and is now due
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Expands Reach of unbuzzd Through AATAC Retail Deal
April 10, 2025
Via
Investor Brand Network
Quantum BioPharma Licensee Celly Nutrition Announces Landmark Partnership with the Asian American Trade Associations Council (AATAC) to Expand Retail Availability of its Alcohol Detox Beverage unbuzzd™
April 10, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Launches Alcohol-Metabolism Beverage in Puerto Rico
April 03, 2025
Via
Investor Brand Network
Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico
April 03, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Partners with Mass General on PET Imaging Study for Multiple Sclerosis
April 01, 2025
Via
Investor Brand Network
Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis
April 01, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Closes $5 Million Offering to Advance Drug Development
March 31, 2025
Via
Investor Brand Network
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.